Table 3.
Factors influencing outcome in patients of SJS/TEN
| Factors | Patients with mortality (n=11) | Patients who survived (n=40) | P |
|---|---|---|---|
| Delay in presentation (mean±SD, in days) | 5.18±2.27 | 5.00±3.62 | 0.87 |
| Diagnosis | |||
| SJS (n=7) | 0 (0%) | 7 (100%) | 0.324 |
| SJS-TEN overlap (n=16) | 3 (18.8%) | 13 (81.2%) | |
| TEN (n=28) | 8 (28.6%) | 20 (71.4%) | |
| Number of involved mucosa (mean±SD) | 2.55±1.04 | 2.53±0.85 | 0.95 |
| Detached BSA, %; mean±SD (median) | 35.37±10.38 (40) | 25.65±11.79 (27.5) | 0.02 |
| SCORTEN (mean±SD) | 3.45±0.82 | 1.85±0.77 | 0.001 |
| SCORTEN components | |||
| Age >40 years | 6/11 (54.5%) | 16/40 (40%) | 0.5 |
| Malignancy present | 0 | 0 | 0 |
| Detached BSA >10% | 11/11 (100%) | 33/40 (82.5%) | 0.32 |
| Blood urea nitrogen >28 mg/dL | 5/11 (45.4%) | 6/40 (15%) | 0.04 |
| Serum HCO3- <20 meq/mL | 7/11 (63.6%) | 9/40 (22.5%) | 0.02 |
| Heart rate >120 beats/min Random blood sugar >252 mg/dL | 5/11 (45.4%) | 7/40 (17.5%) | 0.1 |
| 4/11 (36.3%) | 1/40 (2.5%) | 0.006 | |
| Sepsis | 9/11 (81.8%) | 3/40 (7.5%) | 0.001 |
*BSA: Body surface area, IVIG: Intravenous immunoglobulin, SCORTEN: SCORe of toxic epidermal necrolysis, SD: Standard deviation, SJS: Stevens-Johnson Syndrome, TEN: Toxic epidermal necrolysis